Trials / Conditions / KRAS Mutation-Related Tumors

KRAS Mutation-Related Tumors

14 registered clinical trials studyying KRAS Mutation-Related Tumors — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018	University of California, Irvine	Phase 1 / Phase 2
Not Yet Recruiting	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC NCT06456138	Shanghai Chest Hospital	Phase 1 / Phase 2
Unknown	A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours NCT06237413	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1 / Phase 2
Recruiting	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924	Institut de Recherches Internationales Servier	Phase 1 / Phase 2
Recruiting	NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors NCT05661201	Georgetown University	Phase 1
Terminated	Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574	Biomea Fusion Inc.	Phase 1
Active Not Recruiting	Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies NCT05370469	University of Virginia	N/A
Terminated	Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers NCT04916236	The Netherlands Cancer Institute	Phase 1
Unknown	Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patie NCT05136014	Central Hospital, Nancy, France	—
Terminated	A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRA NCT05071183	Turning Point Therapeutics, Inc.	Phase 1 / Phase 2
Completed	Patogenic Mutation in 5 Genes NCT04976439	Dr Cipto Mangunkusumo General Hospital	—
Completed	Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer NCT04735068	Abramson Cancer Center at Penn Medicine	Phase 2
Completed	A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer NCT03597581	Inspirna, Inc.	Phase 1
Completed	CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer NCT04560270	Poitiers University Hospital	N/A